Recent News

• 10.14.2026 - Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
• 10.08.2026 - Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
• 09.09.2026 - Editas Medicine Reports Inducement Grants to New Chief Medical Officer
• 09.08.2026 - Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
• 09.01.2026 - Editas Medicine to Participate in Upcoming Investor Conferences
• 08.05.2026 - Editas Medicine Announces Second Quarter 2026 Results and Business Updates
• 08.04.2026 - Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
• 08.04.2026 - Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
• 05.28.2026 - Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
• 05.26.2026 - Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Recent Filings

• 10.08.2026 - 8-K Current report
• 09.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2026 - 3 Initial statement of beneficial ownership of securities
• 09.09.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 09.08.2026 - EFFECT Notice of Effectiveness
• 09.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.31.2026 - S-3 Registration statement under Securities Act of 1933
• 08.31.2026 - 144 Report of proposed sale of securities